Systemic combination chemotherapy and intrathecal chemotherapy markedly increased the
survival rate of children with ALL. In the past two decades, the use of minimal (measurable) …

There is considerable interest in and enthusiasm for quantitative tests for residual cancer
cells in the context of cancer therapy, a concept referred to as measurable residual disease …

Cure rates for acute lymphoblastic leukemia (ALL), the most common childhood cancer have
steadily improved over the past five decades. This is due to intensifying systemic therapy …

Abstract KMT2A-rearranged (KMT2A-r) B-cell precursor acute lymphoblastic leukemia (BCP-
ALL) is widely recognized as a high-risk leukemia in both children and adults. However …

Aberrant expression of HOX and MEIS1 family genes, as seen in KMT2A-rearranged,
NUP98-rearranged, or NPM1-mutated leukemias leads to arrested differentiation and …

Neurodevelopmental disorders encompass a group of debilitating diseases presenting with
motor and cognitive dysfunction, with variable age of onset and disease severity. Advances …

Measurable residual disease (MRD)-testing is used in many haematological cancers to
estimate relapse risk and to direct therapy. Sometimes MRD-test results are used for …

Simple Summary Childhood acute lymphoblastic leukemia (ALL) has seen significant
advances in treatment, yet children classified as high-risk still face challenging outcomes …

Background The childhood patients with mixed-lineage leukemia rearrangement (MLL-r)
gene have worse outcome than non-MLL, and thus often treated with high-risk …

Cytogenetic analysis is mandatory at initial assessment of B-cell acute lymphoblastic
leukemia (B-ALL) due to its diagnostic and prognostic value. Results from chromosome …